ity. Expression of the LMP2 and TAP1 genes but not expression of TAP2 or LMP7 is efficiently downregulated, indicating teolytically and present the resulting peptides in association with major histocompatibility complex (MHC) class I molea specific IL-10 effect on the two divergently transcribed TAP1 and LMP2 genes. Downregulation of TAP1 by IL-10 cules to CD8 " cytotoxic T lymphocytes (CTLs). These cells are normally prone to CTL-mediated elimination. However, hampers the transport of peptide antigens into the endoplasmatic reticulum, as shown in the TAP-specific peptide several viruses have evolved strategies to avoid detection by the immune system that interfere with the pathway of transporter assay, their loading onto empty MHC I molecules, and the subsequent translocation to the cell surface. antigen presentation. Epstein-Barr virus (EBV) expresses a predominantly late protein, the BCRF1 gene product vIL-10, As a consequence, IL-10 causes a general reduction of surface MHC I molecules on B lymphocytes that might also that is similar in sequence to the human interleukin-10 (hIL-10). We show here that vIL-10 affects the expression of one affect the recognition of EBV-infected cells by cytotoxic T cells. of the two transporter proteins (TAPs) associated with antigen presentation. Similarly, hIL-10 showed the same activ-᭧ 1997 by The American Society of Hematology.
PSTEIN-BARR VIRUS (EBV) is a human tumor virus
that establishes a life-long latent infection and affects the control of proliferation of infected cells. In particular, (ER), where they are loaded onto empty class I major histocompatibility complex (MHC) molecules in conjunction EBV induces and maintains proliferation of infected human B lymphocytes in vivo and in vitro. In cell culture, this with b2-microglobulin. 8, 9 Subsequently, this complex is transported to the cell surface and presented to class I-reprocess is termed immortalization, but early events during infection and immortalization of primary human B lymphostricted CD8 / cytotoxic T lymphocytes (CTLs). 10, 11 As a consequence, lack of antigen transporters is known to result cytes are far from understood. 1 We applied the differential display technique 2 to identify cellular genes that are reguin the retention of MHC class I molecules in the ER and presentation of empty MHC molecules on the cell surface lated early in response to EBV infection. Primary B lymphocytes from tonsils, adenoids, and peripheral blood were incuwith a dramatically reduced half-life. 12, 13 We show here that EBV produces interleukin-10 (IL-10) to downregulate TAP, bated with supernatants of the EBV-positive marmoset cell line B95.8. 3 These supernatants contain infectious EBV rewhich in turn reduces the cell surface density of class I MHC molecules and affects cellular antigen presentation. Several leased by B95.8 cells that support the lytic cycle of the virus efficiently.
mechanisms of immune escape have been described for different viruses. [14] [15] [16] [17] [18] [19] [20] The use of a cytokine as a mechanism of Differentially expressed RNAs present only in infected or noninfected cells were cloned and sequenced. One of the virus-mediated immunosuppression provides a novel molecular basis for the activities of IL-10 as well as for the advandifferentially expressed RNAs was identified as a partial cDNA encoding a subunit of the transporter associated with tages for EBV in having adopted the homologue of the cellular IL-10 gene. antigen presentation (TAP). The TAP proteins belong to the ATP-dependent family of transporters and are known to play a central role in the transport of peptides derived from pro-
MATERIALS AND METHODS
teolytic degradation in the proteasome. [4] [5] [6] [7] These peptides are RPMI. An aqueous solution of Streptolysin O (Murex, Dartford, UK) was preactivated for 10 minutes at 37ЊC with 4 mmol/L dithiothreitol or were purchased from Biomol (Heidelberg, Germany) and used according to the manufacturer's instructions.
(DTT) and added at a final concentration of 1 U/mL. After incubation on ice for 10 minutes, cells were washed twice with cold RPMI, RNA preparations and Northern blotting. Total cellular RNA was prepared as described. 21 For Northern blots, 10-mg RNA samples resuspended in 650 mL warm translocation buffer (78 mmol/L KCl, 4 mmol/L MgCl 2 , 4 mmol/L CaCl 2 , 5 mmol/L EGTA, 1 mmol/L were used for electrophoresis through 1% agarose formaldehyde gels that were transferred to Hybond N / membranes (Amersham Buchler, DTT, 4 mg/mL bovine serum albumin, 50 mmol/L HEPES/KOH, pH 7.0) and permeabilized for 5 minutes at 37ЊC. Permeabilization Braunschweig, Germany). Molecularly cloned cDNAs for TAP1 and TAP2 were labeled using a random priming kit (Boehringer Mannwas 75% to 85% as determined by trypan blue exclusion. To 150-mL aliquots, 2 U apyrase (Sigma, Deisenhofen, Germany) or 5 mmol/ heim, Mannheim, Germany). Hybridizations were performed as described.
21
L ATP and radiolabeled peptide was added to a final concentration of 300 nmol/L. After incubation for 2.5 minutes at 37ЊC, 800 mL Bochum, Germany) using conventional Fmoc-chemistry. The purity was determined by high-performance liquid chromatography to be was equally diminished (Fig 2A) . No such effect was seen AID Blood 0020 / 5h3d$$$381 07-24-97 00:53:42 blda WBS: Blood after treatment for 48 hours, indicating that the half life of the TAP1 gene product is much longer than its mRNA half life (Fig 3) . These experiments indicate that downregulation of TAP1 is most probably caused by vIL-10 that is present in B95.8 cell culture supernatants. BCRF1 is expressed early during infection. vIL-10, the gene product of the BCRF1 EBV gene, is thought to be expressed during the lytic cycle of EBV, 28 but has also been found to be expressed in primary B cells during early stages of infection. 29 We used an RT-PCR approach to confirm the expression of BCRF1 early after infection of primary B cells. After only 2 days, the expression of BCRF1 was clearly detectable in cells infected with supernatant from B95.8 cells but not with VFS (Fig 4) . BCRF1 is not detectably expressed in established B cells immortalized by EBV in vitro or in EBV-positive Burkitt's lymphoma cell lines (BL); instead, high amounts of cellular IL-10 are often produced. 30 It thus B lymphocytes (Fig 1, lanes 3 through 7, and Fig 3) . because IL-10 has been reported to downregulate CD1, a class I-like but TAP-independent molecule, cytokines such as IL-1a, IL-1b, IL-6, tumor necrosis factor a, and MHC class II molecules on monocytes. [31] [32] [33] [34] Therefore, we analyzed when cells were incubated with supernatants from the EBVthe status of the LMP2 gene (Fig 5) that shares a bidirectional negative Burkitt's lymphoma (BL) cell line DG75 24 (Fig  promoter element with TAP1 , 35 the mRNA levels of LMP7, 2B). We concluded that only a factor produced by the B95. 8 and MHC class I. Steady-state mRNA levels of LMP2 and cell line could be responsible for the observed reduction of TAP1 were found to be downregulated by vIL-10 and hIL-TAP1 expression and that this factor is soluble. A candidate 10 containing supernatants to almost the same extent (Fig  for such a factor is the viral homologue of the cellular human 5). In contrast, B cells incubated with B95.8 supernatant or IL-10 (hIL-10). This gene product is encoded by the EBV recombinant IL-10 cytokine still expressed 80% to 90% of open reading frame BCRF1, exhibits a high sequence simithe levels of class I heavy chain and LMP7 mRNAs in larity to hIL-10, and has similar activities.
25, 26 Thus, vIL-10 comparison with controls (data not shown). We also monihas often been considered as a possible agent for EBV to tored the level of MHC class II molecules in B-cell preparaevade the host's immune system, but its potential mechanism tions by FACS analysis and did not find a reduction of MHC has remained obscure.
class II at the cell surface (data not shown), which is in Recombinant vIL-10 and hIL-10 both reduce the expresagreement with a previous report. 34 sion of TAP1. Recombinant hIL-10 and vIL-10 were pro-
IL-10 downregulates membrane-associated MHC moleduced in Cos7 cells transiently transfected with expression
cules on primary B lymphocytes. Empty class I MHC moleplasmids for vIL-10 or hIL-10. The release of hIL-10 and cules are retained in the ER and only the ternary complex vIL-10 into the supernatant was confirmed using a sandwich of MHC heavy chain, b2-microglobulin, and bound peptide ELISA with monoclonal antibodies specifically directed is stably presented at the cell surface. Cells deficient for TAP against hIL-10 or vIL-10 as described in the Materials and function are not capable of presenting antigens efficiently for Methods. Freshly isolated B lymphocytes were incubated in this reason. 10 Therefore, IL-10-mediated reduction of TAP1 cell culture medium containing recombinant hIL-10 or vILprotein was expected to cause a measurable reduction of 10 at concentrations as in B95.8 supernatants (approximately membrane-associated class I MHC molecules only if reduced 100 to 200 pg/mL), which corresponds to IL-10 serum levels TAP1 protein levels bear biologic significance. FACS analyduring acute EBV infections. 27 After 48 hours, the steadysis with antibodies directed against nonpolymorphic domains state level of TAP1 mRNA in Northern blot hybridizations of MHC class I molecules confirmed the reduction of surface was clearly reduced with both vIL-10 and hIL-10 (Fig 2C) , class I MHCs after incubation of B cells with supernatants similar to the levels seen after incubation with B95.8 supercontaining recombinant vIL-10, hIL-10, B95.8, or VFS (Fig  natant, VFS (Fig 2A) , and highly purified, recombinant hIL-6A). The same effect was observed when purified recombi-10 (Fig 2D) . Protein levels of TAP1 were less dramatically reduced to about one third of that observed in untreated cells nant human IL-10 was used (Fig 6B) .
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IL-10 reduces the amount of peptide translocated into the
TAP activity directly, cells pretreated either with recombinant IL-10, EBV supernatant, VFS, or RPMI only were per-ER. Peptides that are presented in association with MHC class I molecules are generated by proteolytic degradation meabilized with Streptolysin O and the 125 I-labeled peptide RRYQNSTEL was added. Glycosylated peptides were then in the cytoplasm by proteasomes. Subsequently, antigenic peptides are translocated into the ER by TAP heterodimers trapped with immobilized, matrix-coupled Concanavalin A and the amount of translocated peptide, which is a direct acting as peptide transporters and loaded onto empty MHC I molecules. The addition of N-linked glycan onto peptides measure of TAP activity, was determined by g-counting of lectin-eluted peptide. As shown in Fig 7, incubation of pricontaining an N-linked glycosylation consensus site (NST; single letter code) also takes place in the ER. 36 TAP activity mary B lymphocytes with recombinant IL-10, B95.8 supernatant, or VFS resulted in an approximately 50% reduction can be determined in a peptide translocation assay 13 that should allow us to discriminate between direct IL-10 effects of translocated peptide in comparison to cells incubated with RPMI only. Because peptide translocation was strictly ATPon functional TAP levels and indirect effects on the expression of LMP2 involved in peptide processing. To measure dependent, the amount of translocated peptide can be directly AID Blood 0020 / 5h3d$$$381 07-24-97 00:53:42 blda WBS: Blood 10 has also been found to interfere with the MHC class I antigen presenting pathway, but the mechanism of this attributed to TAP activity. The magnitude of reduced TAP observation remained unclear. 41 We now provide an explanaactivity is in agreement with the results of the 51 Cr-release tion in that hIL-10 as well as vIL-10 are equally capable of assay indicating that IL-10-induced downregulation of downregulating TAP1 expression, thereby interfering with TAP1 is capable of affecting antigen peptide transport in a the loading of MHC class I molecules, resulting in empty functionally relevant manner.
and unstable MHC class I/b2-microglobulin complexes. showed a protective effect of IL-10 against target cell lysis elevated levels of TAP1 mRNA compared with primary B lymphocytes treated with IL-10 (Fig 1) . These cell lines also that is known to depend on the amout of surface MHC class I molecules (data not shown). This finding also indicates express the viral LMP1 gene product that is suspected to activate the TAP1 promoter through the NFk-B/Rel paththat IL-10 can modulate TAP1 expression even on the background of very different initial TAP1 levels.
way. 35, 43 Thus, the effect of vIL-10 on TAP1 expression is most likely reversed by LMP1 and, as a consequence, in Immortalized EBV-infected B-lymphocyte cell lines express hIL-10 in vitro (data not shown) but nevertheless show vitro established immortalized human B lymphocytes are 
